Table 3.
Venous Thromboembolism Prophylaxis of Study Cohorts.
| Stratified by Age-Group | Stratified by Baseline Renal Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <65 Years | 65-74 Years | ≥75 years | With | Without | ||||||||
| n | % | n | % | n | % | P Value | n | % | n | % | P Value | |
| Inpatient VTE prophylaxis | 3648 | 33.9 | 1254 | 44.7 | 1941 | 44.7 | <.001 | 2281 | 38.7 | 4562 | 38.0 | .36 |
| Anticoagulants | <.001 | <.001 | ||||||||||
| Enoxaparin only | 3083 | 84.5 | 915 | 73.0 | 1253 | 64.6 | 1554 | 68.1 | 3697 | 81.0 | ||
| Enoxaparin + Warfarin | 143 | 3.9 | 77 | 6.1 | 142 | 7.3 | 138 | 6.1 | 224 | 4.9 | ||
| DOAC only | 50 | 1.4 | 27 | 2.2 | 57 | 2.9 | 51 | 2.2 | 83 | 1.8 | ||
| Warfarin only | 348 | 9.5 | 224 | 17.9 | 471 | 24.3 | 511 | 22.4 | 532 | 11.7 | ||
| Othera | 24 | 0.7 | 11 | 0.9 | 18 | 0.9 | 27 | 1.2 | 26 | 0.6 | ||
| Outpatient VTE prophylaxis | 835 | 7.8 | 285 | 10.2 | 618 | 14.2 | <.001 | 725 | 12.3 | 1013 | 8.4 | <.001 |
| Anticoagulants | <.001 | <.001 | ||||||||||
| Enoxaparin only | 122 | 14.6 | 20 | 7.0 | 34 | 5.5 | 49 | 6.8 | 127 | 12.5 | ||
| Enoxaparin + Warfarin | 70 | 8.4 | 28 | 9.8 | 34 | 5.5 | 46 | 6.3 | 86 | 8.5 | ||
| DOAC only | 65 | 7.8 | 57 | 20.0 | 116 | 18.8 | 88 | 12.1 | 150 | 14.8 | ||
| Warfarin only | 299 | 35.8 | 121 | 42.5 | 341 | 55.2 | 317 | 43.7 | 444 | 43.8 | ||
| Othera | 279 | 33.4 | 59 | 20.7 | 93 | 15.1 | 225 | 31.0 | 206 | 20.3 | ||
Abbreviations: DOAC, direct oral anticoagulant; VTE, venous thromboembolism.
a Includes other anticoagulant combinations not listed above as well as the use of other anticoagulants, such as fondaparinux.